Style | Citing Format |
---|---|
MLA | Hedayati N, et al.. "Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome." Pathology Research and Practice, vol. 261, no. , 2024, pp. -. |
APA | Hedayati N, Safaei Naeini M, Ale Sahebfosoul MM, Mafi A, Eshaghi Milasi Y, Rizaneh A, Nabavi N, Farahani N, Alimohammadi M, Ghezelbash B (2024). Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome. Pathology Research and Practice, 261(), -. |
Chicago | Hedayati N, Safaei Naeini M, Ale Sahebfosoul MM, Mafi A, Eshaghi Milasi Y, Rizaneh A, Nabavi N, Farahani N, Alimohammadi M, Ghezelbash B. "Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome." Pathology Research and Practice 261, no. (2024): -. |
Harvard | Hedayati N et al. (2024) 'Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome', Pathology Research and Practice, 261(), pp. -. |
Vancouver | Hedayati N, Safaei Naeini M, Ale Sahebfosoul MM, Mafi A, Eshaghi Milasi Y, Rizaneh A, et al.. Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome. Pathology Research and Practice. 2024;261():-. |
BibTex | @article{ author = {Hedayati N and Safaei Naeini M and Ale Sahebfosoul MM and Mafi A and Eshaghi Milasi Y and Rizaneh A and Nabavi N and Farahani N and Alimohammadi M and Ghezelbash B}, title = {Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome}, journal = {Pathology Research and Practice}, volume = {261}, number = {}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Hedayati N AU - Safaei Naeini M AU - Ale Sahebfosoul MM AU - Mafi A AU - Eshaghi Milasi Y AU - Rizaneh A AU - Nabavi N AU - Farahani N AU - Alimohammadi M AU - Ghezelbash B TI - Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome JO - Pathology Research and Practice VL - 261 IS - SP - EP - PY - 2024 ER - |